Legend Biotech (LEGN) Net Margin (2019 - 2026)
Legend Biotech's (LEGN) quarterly Net Margin came in at 18.03% in Q1 2026, up 3372.0% YoY from 0.52% in Q1 2025, and down 78.69% on a QoQ basis from 10.09% in Q4 2025.
Powered by 
Analysis
Legend Biotech (LEGN) Net Margin (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Net Margin data on file, last reported at 18.03% in Q1 2026.
- Quarterly Net Margin rose 3372.0% year-over-year to 18.03% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21.83% (up 1985.0% YoY) and the FY2025 annual result came in at 28.85%, up 125.0% from the prior year.
- Net Margin fell to 18.03% in Q1 2026, from 10.09% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 0.11% in Q4 2023 to a low of 1614.13% in Q2 2022.
- A 5-year average of 203.05% and a median of 63.62% in 2024 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin sank 246707 bps — and 2023, when it surged 134258 bps.
- Tracing LEGN's Net Margin over 5 years: stood at 491.72% in 2022, then jumped by 100 bps to 0.11% in 2023, then tumbled by 28331 bps to 31.68% in 2024, then jumped by 68 bps to 10.09% in 2025, then tumbled by 79 bps to 18.03% in 2026.
- The last three Net Margin figures came in at 18.03% (Q1 2026), 10.09% (Q4 2025), and 14.12% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 20.08% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20.08% |
| Mar 31, 2026 | -17.01% |
| Dec 31, 2025 | -2.78% |
| Sep 30, 2025 | -14.12% |
| Jun 30, 2025 | -48.69% |
| Mar 31, 2025 | 31.14% |
| Dec 31, 2024 | -31.68% |
| Sep 30, 2024 | 38.64% |
| Jun 30, 2024 | -5.65% |
| Mar 31, 2024 | -51.06% |
| Dec 31, 2023 | -111.43% |
| Sep 30, 2023 | -21.08% |
| Jun 30, 2023 | -9.50% |
| Mar 31, 2023 | 37.17% |
| Dec 31, 2022 | -491.72% |
| Sep 30, 2022 | -310.50% |
| Jun 30, 2022 | -1,614.13% |
| Mar 31, 2022 | -64.53% |
| Dec 31, 2021 | -226.53% |
| Sep 30, 2021 | 16.73% |